Intestinal absorption mechanism of mirabegron, a potent and selective β3-adrenoceptor agonist: Involvement of human efflux and/or influx transport systems

Molecular Pharmaceutics

Volumn 10, Issue 5, 2013, Pages 1783-1794

  Takusagawa, Shin ^a   Ushigome, Fumihiko ^a   Nemoto, Hiroyuki ^b   Takahashi, Yutaka ^a   Li, Qun ^c   Kerbusch, Virginie ^d   Miyashita, Aiji ^a   Iwatsubo, Takafumi ^a   Usui, Takashi ^a  

^a ASTELLAS PHARMA INC   (Japan)

^b SEKISUI CHEMICAL CO LTD   (Japan)

^c Astellas Pharma Global Development   (Netherlands)

^d PharmAspire Consulting   (Netherlands)

Author keywords

Caco 2; dose dependent oral bioavailability; double peak pharmacokinetic profile; intestinal absorption; membrane permeability; mirabegron; OATP1A2; P glycoprotein; transporter

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; METOPROLOL; MIRABEGRON; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; NADOLOL; PEPTIDE TRANSPORTER 1; PROPRANOLOL; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ACETANILIDE DERIVATIVE; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; COTRANSPORTER; ORGANIC ANION TRANSPORTER; RECOMBINANT PROTEIN; SLC15A1 PROTEIN, HUMAN; SLCO1A2 PROTEIN, HUMAN; SLCO2B1 PROTEIN, HUMAN; THIAZOLE DERIVATIVE; TUMOR PROTEIN;

ANIMAL CELL; APICAL MEMBRANE; ARTICLE; BASEMENT MEMBRANE; CELL VACUOLE; CONTROLLED STUDY; DRUG UPTAKE; EFFUSION; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; MEMBRANE PERMEABILITY; MEMBRANE TRANSPORT; NONHUMAN; OOCYTE; PH; PRIORITY JOURNAL; PROTEIN TRANSPORT; STANDARD; TRANSCYTOSIS; XENOPUS LAEVIS; ACTIVE TRANSPORT; ANIMAL; BIOAVAILABILITY; CACO 2 CELL LINE; CELL MEMBRANE PERMEABILITY; FEMALE; HEK293 CELL LINE; LLC PK1 CELL LINE; METABOLISM; PHYSIOLOGY; PIG; URINARY BLADDER, OVERACTIVE;

ACETANILIDES; ADRENERGIC BETA-3 RECEPTOR AGONISTS; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT, ACTIVE; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; FEMALE; HEK293 CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; LLC-PK1 CELLS; NEOPLASM PROTEINS; OOCYTES; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; RECOMBINANT PROTEINS; SWINE; SYMPORTERS; THIAZOLES; URINARY BLADDER, OVERACTIVE; XENOPUS LAEVIS;

EID: 84877311844     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300582s     Document Type: Article

References (54)

1. Takasu, T.; Ukai, M.; Sato, S.; Matsui, T.; Nagase, I.; Maruyama, T.; Sasamata, M.; Miyata, K.; Uchida, H.; Yamaguchi, O. Effect of (R)-2-(2-aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function J. Pharmacol. Exp. Ther. 2007, 321, 642-7
2. Athanasopoulos, A.; Giannitsas, K. An overview of the clinical use of antimuscarinics in the treatment of overactive bladder Adv. Urol. 2011, 2011, 820816
3. Khullar, V.; Amarenco, G.; Angulo, J. C.; Cambronero, J.; Hoye, K.; Milsom, I.; Radziszewski, P.; Rechberger, T.; Boerrigter, P.; Drogendijk, T.; Wooning, M.; Chapple, C. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: Results from a randomised European-Australian phase 3 trial Eur. Urol. 2013, 63, 283-95
4. Nitti, V.; Auerbach, S.; Martin, N.; Calhoun, A.; Lee, M.; Herschorn, S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder J. Urol. 2013, 189, 1388-95
5. Takusagawa, S.; van Lier, J. J.; Suzuki, K.; Nagata, M.; Meijer, J.; Krauwinkel, W.; Schaddelee, M.; Sekiguchi, M.; Miyashita, A.; Iwatsubo, T.; van Gelderen, M.; Usui, T. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective beta(3)-adrenoceptor agonist, after oral administration to healthy male volunteers Drug Metab. Dispos. 2012, 40, 815-24
6. Michel, M. C.; Korstanje, C.; Krauwinkel, W. M, K. The pharmacokinetic profile of tamsulosin oral controlled absorption system (OCAS(R)) Eur. Urol. 2005, Suppl. 4) 15-24
7. Eltink, C.; Lee, J.; Schaddelee, M.; Zhang, W.; Kerbusch, V.; Meijer, J.; van Marle, S.; Grunenberg, N.; Kowalski, D.; Drogendijk, T.; Moy, S.; Iitsuka, H.; van Gelderen, M.; Matsushima, H.; Sawamoto, T. Single dose pharmacokinetics and absolute bioavailability of mirabegron, a beta3-adrenoceptor agonist for treatment of overactive bladder Int. J. Clin. Pharmacol. Ther. 2012, 50, 838-49
8. Krauwinkel, W.; van Dijk, J.; Schaddelee, M.; Eltink, C.; Meijer, J.; Strabach, G.; van Marle, S.; Kerbusch, V.; van Gelderen, M. Pharmacokinetic properties of mirabegron, a beta3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women Clin. Ther. 2012, 34, 2144-60
9. 3- adrenoceptor agonist Xenobiotica 2012, 42, 957-967
10. Ogihara, T.; Kamiya, M.; Ozawa, M.; Fujita, T.; Yamamoto, A.; Yamashita, S.; Ohnishi, S.; Isomura, Y. What kinds of substrates show P-glycoprotein- dependent intestinal absorption? Comparison of verapamil with vinblastine Drug Metab. Pharmacokinet. 2006, 21, 238-44
11. Cao, X.; Yu, L. X.; Barbaciru, C.; Landowski, C. P.; Shin, H. C.; Gibbs, S.; Miller, H. A.; Amidon, G. L.; Sun, D. Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability Mol. Pharmaceutics 2005, 2, 329-40
12. Adachi, Y.; Suzuki, H.; Sugiyama, Y. Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein Pharm. Res. 2001, 18, 1660-8
13. Ishiguro, N.; Maeda, K.; Kishimoto, W.; Saito, A.; Harada, A.; Ebner, T.; Roth, W.; Igarashi, T.; Sugiyama, Y. Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide Drug Metab. Dispos. 2006, 34, 1109-15
14. Noé, J.; Portmann, R.; Brun, M. E.; Funk, C. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3 Drug Metab. Dispos. 2007, 35, 1308-14
15. Umehara, K.; Iwai, M.; Adachi, Y.; Iwatsubo, T.; Usui, T.; Kamimura, H. Hepatic uptake and excretion of (-)-N-{2-[(R)-3-(6,7-dimethoxy-1,2,3,4- tetrahydroisoquinoline-2-carbonyl)piperidi no]ethyl}-4-fluorobenzamide (YM758), a novel if channel inhibitor, in rats and humans Drug Metab. Dispos. 2008, 36, 1030-8
16. Ito, K.; Kato, Y.; Tsuji, H.; Nguyen, H. T.; Kubo, Y.; Tsuji, A. Involvement of organic anion transport system in transdermal absorption of flurbiprofen J. Controlled Release 2007, 124, 60-8
17. Hidalgo, I. J.; Raub, T. J.; Borchardt, R. T. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability Gastroenterology 1989, 96, 736-49
18. Dahan, A.; Amidon, G. L. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting Am. J. Physiol. 2009, 297, G371-7
19. Xia, C. Q.; Liu, N.; Yang, D.; Miwa, G.; Gan, L. S. Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells Drug Metab. Dispos. 2005, 33, 637-43
20. Hogben, C. A.; Tocco, D. J.; Brodie, B. B.; Schanker, L. S. On the mechanism of intestinal absorption of drugs J. Pharmacol. Exp. Ther. 1959, 125, 275-82
21. Lennernas, H.; Regardh, C. G. Evidence for an interaction between the beta-blocker pafenolol and bile salts in the intestinal lumen of the rat leading to dose-dependent oral absorption and double peaks in the plasma concentration-time profile Pharm. Res. 1993, 10, 879-83
22. Lipka, E.; Lee, I. D.; Langguth, P.; Spahn-Langguth, H.; Mutschler, E.; Amidon, G. L. Celiprolol double-peak occurrence and gastric motility: nonlinear mixed effects modeling of bioavailability data obtained in dogs J. Pharmacokinet. Biopharm. 1995, 23, 267-86
23. Yin, O. Q.; Tomlinson, B.; Chow, A. H.; Chow, M. S. A modified two-portion absorption model to describe double-peak absorption profiles of ranitidine Clin. Pharmacokinet. 2003, 42, 179-92
24. Mostafavi, S. A.; Foster, R. T. Influence of cimetidine co-administration on the pharmacokinetics of acebutolol enantiomers and its metabolite diacetolol in a rat model: the effect of gastric pH on double-peak phenomena Int. J. Pharm. 2003, 255, 81-6
25. Piyapolrungroj, N.; Zhou, Y. S.; Li, C.; Liu, G.; Zimmermann, E.; Fleisher, D. Cimetidine absorption and elimination in rat small intestine Drug Metab. Dispos. 2000, 28, 65-72
26. Wermeling, D. P.; Miller, J. L.; Archer, S. M.; Manaligod, J. M.; Rudy, A. C. Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration J. Clin. Pharmacol. 2001, 41, 1225-31
27. Weitschies, W.; Bernsdorf, A.; Giessmann, T.; Zschiesche, M.; Modess, C.; Hartmann, V.; Mrazek, C.; Wegner, D.; Nagel, S.; Siegmund, W. The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen Pharm. Res. 2005, 22, 728-35
28. Amidon, G. L.; Lennernas, H.; Shah, V. P.; Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 1995, 12, 413-20
29. U.S. FDA Guidance for Industry-Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm070246.pdf (Dec 22, 2012).
30. Palm, K.; Luthman, K.; Ros, J.; Grasjo, J.; Artursson, P. Effect of molecular charge on intestinal epithelial drug transport: pH-dependent transport of cationic drugs J. Pharmacol. Exp. Ther. 1999, 291, 435-43
31. Yamashita, S.; Furubayashi, T.; Kataoka, M.; Sakane, T.; Sezaki, H.; Tokuda, H. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells Eur. J. Pharm. Sci. 2000, 10, 195-204
32. Boisset, M.; Botham, R. P.; Haegele, K. D.; Lenfant, B.; Pachot, J. I. Absorption of angiotensin II antagonists in Ussing chambers, Caco-2, perfused jejunum loop and in vivo: importance of drug ionisation in the in vitro prediction of in vivo absorption Eur. J. Pharm. Sci. 2000, 10, 215-24
33. Artursson, P.; Karlsson, J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells Biochem. Biophys. Res. Commun. 1991, 175, 880-5
34. Yamashita, S.; Tanaka, Y.; Endoh, Y.; Taki, Y.; Sakane, T.; Nadai, T.; Sezaki, H. Analysis of drug permeation across Caco-2 monolayer: implication for predicting in vivo drug absorption Pharm. Res. 1997, 14, 486-91
35. Yee, S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in mañfact or myth Pharm. Res. 1997, 14, 763-6
36. Chong, S.; Dando, S. A.; Soucek, K. M.; Morrison, R. A. In vitro permeability through caco-2 cells is not quantitatively predictive of in vivo absorption for peptide-like drugs absorbed via the dipeptide transporter system Pharm. Res. 1996, 13, 120-3
37. Chiou, W. L.; Chung, S. M.; Wu, T. C.; Ma, C. A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans Int. J. Clin. Pharmacol. Ther. 2001, 39, 93-101
38. Taylor, D. C.; Pownall, R.; Burke, W. The absorption of beta-adrenoceptor antagonists in rat in-situ small intestine; the effect of lipophilicity J. Pharm. Pharmacol. 1985, 37, 280-3
39. Neuhoff, S.; Ungell, A. L.; Zamora, I.; Artursson, P. pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions Pharm. Res. 2003, 20, 1141-8
40. Evans, D. F.; Pye, G.; Bramley, R.; Clark, A. G.; Dyson, T. J.; Hardcastle, J. D. Measurement of gastrointestinal pH profiles in normal ambulant human subjects Gut 1988, 29, 1035-41
41. Giacomini, K. M.; Huang, S. M.; Tweedie, D. J.; Benet, L. Z.; Brouwer, K. L.; Chu, X.; Dahlin, A.; Evers, R.; Fischer, V.; Hillgren, K. M.; Hoffmaster, K. A.; Ishikawa, T.; Keppler, D.; Kim, R. B.; Lee, C. A.; Niemi, M.; Polli, J. W.; Sugiyama, Y.; Swaan, P. W.; Ware, J. A.; Wright, S. H.; Yee, S. W.; Zamek-Gliszczynski, M. J.; Zhang, L. Membrane transporters in drug development Nat. Rev. Drug Discovery 2010, 9, 215-36
42. Regardh, C. G.; Heggelund, A.; Kylberg-Hanssen, K.; Lundborg, P. Pharmacokinetics of pafenolol after i.v. and oral administration of three separate doses of different strength to man Biopharm. Drug Dispos. 1990, 11, 607-17
43. Karlsson, J.; Kuo, S. M.; Ziemniak, J.; Artursson, P. Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein Br. J. Pharmacol. 1993, 110, 1009-16
44. Wetterich, U.; Spahn-Langguth, H.; Mutschler, E.; Terhaag, B.; Rosch, W.; Langguth, P. Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo Pharm. Res. 1996, 13, 514-22
45. Doppenschmitt, S.; Spahn-Langguth, H.; Regardh, C. G.; Langguth, P. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein J. Pharm. Sci. 1999, 88, 1067-72
46. Berggren, S.; Gall, C.; Wollnitz, N.; Ekelund, M.; Karlbom, U.; Hoogstraate, J.; Schrenk, D.; Lennernas, H. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine Mol. Pharmaceutics 2007, 4, 252-7
47. Wada, S.; Kano, T.; Mita, S.; Idota, Y.; Morimoto, K.; Yamashita, F.; Ogihara, T. The role of inter-segmental differences in P-glycoprotein expression and activity along the rat small intestine in causing the double-peak phenomenon of substrate plasma concentration. Drug Metab. Pharmacokinet. 2013, 28, 98-103.
48. Kato, Y.; Miyazaki, T.; Kano, T.; Sugiura, T.; Kubo, Y.; Tsuji, A. Involvement of multidrug resistance-associated protein 1 in intestinal toxicity of methotrexate J. Pharm. Sci. 2009, 98, 2529-39
49. Shirasaka, Y.; Kuraoka, E.; Spahn-Langguth, H.; Nakanishi, T.; Langguth, P.; Tamai, I. Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat J. Pharmacol. Exp. Ther. 2010, 332, 181-9
50. Groneberg, D. A.; Doring, F.; Eynott, P. R.; Fischer, A.; Daniel, H. Intestinal peptide transport: ex vivo uptake studies and localization of peptide carrier PEPT1 Am. J. Physiol. 2001, 281, G697-704
51. Terada, T.; Inui, K. Peptide transporters: structure, function, regulation and application for drug delivery Curr. Drug Metab. 2004, 5, 85-94
52. Glaeser, H.; Bailey, D. G.; Dresser, G. K.; Gregor, J. C.; Schwarz, U. I.; McGrath, J. S.; Jolicoeur, E.; Lee, W.; Leake, B. F.; Tirona, R. G.; Kim, R. B. Intestinal drug transporter expression and the impact of grapefruit juice in humans Clin. Pharmacol. Ther. 2007, 81, 362-70
53. Kobayashi, D.; Nozawa, T.; Imai, K.; Nezu, J.; Tsuji, A.; Tamai, I. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane J. Pharmacol. Exp. Ther. 2003, 306, 703-8
54. Nishimura, M.; Naito, S. Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies Drug Metab. Pharmacokinet. 2005, 20, 452-77